Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Documenti analoghi

• Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
  di: Takahiro Kinami, et al.
  Pubblicazione: (2024)
• A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population
  di: Yuanlin Zou, et al.
  Pubblicazione: (2024)
• A clinical‐radiomic‐pathomic model for prognosis prediction in patients with hepatocellular carcinoma after radical resection
  di: Qu Xie, et al.
  Pubblicazione: (2024)
• Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing
  di: Linlin Zheng, et al.
  Pubblicazione: (2024)
• Risk factors for lenvatinib‐induced palmar‐plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study
  di: Shusuke Uekusa, et al.
  Pubblicazione: (2024)